The company got the nod to manufacture and market apalutamide tablets, 60 mg, the generic equivalent of Erleada tablets, 60 ...

Zydus Lifesciences rose 3% to an intra-day high of Rs 930 after the company received approval from the US FDA to manufacture ...

The rise in the Zydus Lifesciences shares came after the company received final approval from the United States Food and Drug ...

The uptick in the Zydus Life shares came after the company received final approval from the USFDA to manufacture Eluxadoline Tablets, 75 mg and 100 mg ...

The approval covers Apalutamide tablets of 60 mg strength, the company said in a regulatory filing. The drug will be ...

Zydus Lifesciences shares rose nearly 2% to Rs 899.40 after receiving USFDA approval to manufacture Eluxadoline Tablets (75 mg & 100 mg) for IBS-D treatment. The company secured 180 days of shared ...

Ahmedabad: Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Eluxadoline Tablets, 75 mg and 100 mg (USRLD: ...

Zydus Lifesciences shares rose 8.34 per cent on March 19, touching an intraday high of Rs 910.30  at 1:00 PM when the company ...

Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive ...

Eluxadoline tablets will be produced at Zydus Lifesciences Ltd (SEZ) in Ahmedabad, the company said in an exchange filing.

Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration to manufacture Apalutamide Tablets, 60 mg.